Indinavir

Modify Date: 2024-01-02 09:51:49

Indinavir structure	Common Name	Indinavir
	CAS Number	150378-17-9	Molecular Weight	613.789
	Density	1.2±0.1 g/cm3	Boiling Point	831.6±75.0 °C at 760 mmHg
	Molecular Formula	C₃₆H₄₇N₅O₄	Melting Point	150-153ºC
	MSDS	N/A	Flash Point	456.8±37.1 °C

Use of Indinavir

Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.Target: HIV ProteaseIndinavir(MK-639) is a protease inhibitor used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.MK-639 appears to have significant dose-related antiviral activity and is well tolerated [1]. Inhibition constants (K(i)) of the antiviral drug indinavir for the reaction catalyzed by the mutant enzymes were about threefold and 50-fold higher for PR(L24I) and PR(I50V), respectively, relative to PR and PR(G73S). The dimer dissociation constant (K(d)) was estimated to be approximately 20 nM for both PR(L24I) and PR(I50V), and below 5 nM for PR(G73S) and PR. Crystal structures of the mutants PR(L24I), PR(I50V) and PR(G73S) were determined in complexes with indinavir, or the p2/NC substrate analog at resolutions of 1.10-1.50 Angstrom [2].

Name	indinavir
Synonym	More Synonyms

Description	Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.Target: HIV ProteaseIndinavir(MK-639) is a protease inhibitor used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.MK-639 appears to have significant dose-related antiviral activity and is well tolerated [1]. Inhibition constants (K(i)) of the antiviral drug indinavir for the reaction catalyzed by the mutant enzymes were about threefold and 50-fold higher for PR(L24I) and PR(I50V), respectively, relative to PR and PR(G73S). The dimer dissociation constant (K(d)) was estimated to be approximately 20 nM for both PR(L24I) and PR(I50V), and below 5 nM for PR(G73S) and PR. Crystal structures of the mutants PR(L24I), PR(I50V) and PR(G73S) were determined in complexes with indinavir, or the p2/NC substrate analog at resolutions of 1.10-1.50 Angstrom [2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Protease Signaling Pathways >> Anti-infection >> HIV Research Areas >> Inflammation/Immunology
References	[1]. Stein, D.S., et al., A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS, 1996. 10(5): p. 485-92. [2]. Liu, F., et al., Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol, 2005. 354(4): p. 789-800.

Description

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Protease

Signaling Pathways >> Anti-infection >> HIV

Research Areas >> Inflammation/Immunology

References

[1]. Stein, D.S., et al., A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS, 1996. 10(5): p. 485-92.

[2]. Liu, F., et al., Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol, 2005. 354(4): p. 789-800.

Density	1.2±0.1 g/cm3
Boiling Point	831.6±75.0 °C at 760 mmHg
Melting Point	150-153ºC
Molecular Formula	C₃₆H₄₇N₅O₄
Molecular Weight	613.789
Flash Point	456.8±37.1 °C
Exact Mass	613.362793
PSA	118.03000
LogP	4.04
Vapour Pressure	0.0±3.2 mmHg at 25°C
Index of Refraction	1.629
Storage condition	2-8℃

Precursor 7
CAS#:6959-48-4 3-Chloromethylp... CAS#:150323-38-9 9-BENZHYDRYLIDE... CAS#:848482-93-9 (S)-4-N-Boc-Pip... CAS#:150407-69-5 (S)-N-4-Boc-N-1...
CAS#:150323-35-6 (S)-TERT-BUTYL ... CAS#:150323-36-7 dihydro-5(S)-[[... CAS#:32780-06-6 (5S)-5-(Hydroxy...
DownStream 0

(1(1S,2R)5(S))-2,3,5-TRIDEOXY-N-(2,3-DIHYDRO-2HYDROXY-1H-INDEN-1-YI)

(2S)-1-[(2S,4R,5E)-4-Benzyl-2,5-dihydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]imino}pentyl]-N-(2-methyl-2-propanyl)-4-(3-pyridinylmethyl)-2-piperazinecarboximidic acid (non-preferred name)

(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide

(2S)-1-[(2S,4R)-4-Benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-(2-methyl-2-propanyl)-4-(3-pyridinylmethyl)-2-piperazinecarboxamide

(2S)-1-[(2S,4R)-4-Benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide (non-preferred name)

N-[2(R)-hydroxy-1(S)-indanyl]-5-{[2(S)-tert-butylaminocarbonyl]-4-(3-pyridylmethyl)piperazino}-4(S)-hydroxy-2(R)-phenylmethylpentanamide

(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tertbutyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide

Indinavir